Impact of randomized clinical trial results in the National Comprehensive Cancer Network on the use of tamoxifen after breast surgery for ductal carcinoma in situ

Journal of Clinical Oncology

Volumn 25, Issue 22, 2007, Pages 3251-3258

  Yen, Tina W F ^a   Kuerer, Henry M ^a   Ottesen, Rebecca A ^a   Rouse, Layla ^a   Niland, Joyce C ^a   Edge, Stephen B ^a   Theriault, Richard L ^a   Weeks, Jane C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST DUCT; BREAST SURGERY; CANCER CENTER; CARCINOMA IN SITU; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS; TAMOXIFEN; UNITED STATES;

EID: 34548277592     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.2699     Document Type: Article

References (20)

1. Fentiman IS: The dilemma of in situ carcinoma of the breast. Int J Clin Pract 55:680-683, 2001
2. American Cancer Society: Cancer Facts & Figures 2007. http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf
3. Solin LJ, Recht A, Fourquet A, et al: Ten-year results of breast-conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast. Cancer 68:2337-2344, 1991
4. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
5. Fisher B, Land S, Mamounas E, et al: Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semm Oncol 28:400-418, 2001
6. Carlson RW, Anderson BO, Burstein HJ, et al: National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines in Oncology, v 2.2006. http://www.nccn.org/professionals/physicians_gls/PDF/breast.pdf
7. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
8. Katz JN, Chang LC, Sangha O, et al: Can comorbidity be measured by questionnaire rather than medical record review? Med Care 34:73-84, 1996
9. Yen TW, Hunt KK, Mirza NQ, et al: Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ. Cancer 100:942-949, 2004
10. Nakhlis F, Lazarus L, Hou N, et al: Tamoxifen use in patients with ductal carcinoma in situ and T1a/b NO invasive carcinoma. J Am Coll Surg 201:688-694, 2005
11. Hird RB, Chang A, Cimmino V, et al: Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. Cancer 106:2113-2118, 2006
12. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
13. Cuzick J: Future possibilities in the prevention of breast cancer: Breast cancer prevention trials. Breast Cancer Res 2:258-263, 2000
14. Allred D, Bryant J, Land S, et al: Estrogen receptor expression as a predictive marker of the effective of tamoxifen in the treatment of DCIS: Findings from NSABP protocol B-24. Presented at 25th Annual San Antonio Breast Cancer Symposium, December 11-14, 2002, San Antonio, TX
15. Houghton J: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomized controlled trial. Lancet 362:95-102, 2003
16. Howell A, Buzdar A: Are aromatase inhibitors superior to antiestrogens? J Steroid Biochem Mol Biol 93:237-247, 2005
17. Howell A, Cuzick J, Baum M, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62, 2005
18. Vogel VG, Costantino JP, Wickerham DL, et al: National Surgical Adjuvant Breast and Bowel Project update: Prevention trials and endocrine therapy of ductal carcinoma in situ. Clin Cancer Res 9:495S-501S, 2003
19. Cuzick J: Aromatase inhibitors in prevention: Data from the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163:96-103, 2003
20. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295:2727-2741, 2006